Journal of Pharmaceutical and Biological Research
ISSN: 2347-8330 | https://doi.org/10.30904/j.jpbr.2026.4983

Artificial Intelligence in Pharmaceutical Regulatory Compliance: Data Integrity, AI Validation, and Digital QA Systems

I. Jai Surya[1*], V. Brindha Shree[1], J. Abdul Basith[1], J. Balagopal[1], P. Dharshini[1], Ravisankar Mathesan[1], Nataraj Palaniyappan[2]

[1,1]Srinivasan College of Pharmaceutical Sciences, Trichy*
[1]Scientist, Novitium Pharma LLC, New jersey, USA.
***Corresponding E-Mail:** jaisurya5703@gmail.com*

Received: 25-02- 2026 | Revised: 14-03- 2026 | Accepted: 27-04- 2026 | Published: 14-05-2026

ABSTRACT
Artificial Intelligence (AI) is increasingly transforming pharmaceutical industries by enhancing data integrity, audit trail compliance, electronic documentation, AI validation, and digital quality assurance systems. Modern pharmaceutical manufacturing and analytical laboratories generate large volumes of digital data that require secure management, accurate documentation, and continuous regulatory compliance. Conventional manual quality systems are often time-consuming, error-prone, and difficult to manage efficiently in highly regulated environments. The integration of AI technologies into pharmaceutical quality and compliance systems enables intelligent automation, predictive monitoring, and real-time decision-making.AI-driven systems improve data integrity by identifying inconsistencies, detecting abnormal data patterns, and minimizing the risk of unauthorized data manipulation. Advanced machine learning algorithms support automated audit trail review, anomaly detection, and risk-based compliance monitoring. AI-assisted electronic documentation systems enhance data accuracy, reduce manual transcription errors, and improve workflow efficiency through automated report generation and intelligent document management.AI validation has become essential to ensure the reliability, reproducibility, and regulatory acceptance of machine learning models used in pharmaceutical operations. Additionally, AI-integrated digital quality assurance systems support predictive quality monitoring, deviation management, CAPA activities, and real-time process control. These technologies improve operational efficiency, strengthen regulatory compliance, and enhance product quality. This review highlights the applications, benefits, challenges, and future perspectives of AI integration in pharmaceutical data integrity and digital quality management systems.
Keywords: Artificial Intelligence, Data Integrity, Audit Trail Compliance, Digital Quality Assurance, Pharmaceutical Industries

Introduction

The pharmaceutical industry is one of the most highly regulated sectors in the world, where maintaining product quality, patient safety, and regulatory compliance is of utmost importance [1]. Pharmaceutical manufacturing and analytical laboratories generate enormous volumes of data during drug development, quality control, stability studies, manufacturing operations, and batch release activities [2]. Ensuring the accuracy, reliability, consistency, and traceability of this data is essential for maintaining regulatory standards and preventing risks associated with product quality and patient safety [3]. Regulatory authorities such as the US Food and Drug Administration, European Medicines Agency, and International Council for Harmonisation emphasize strict compliance with data integrity, audit trail management, electronic documentation, and digital quality assurance practices in pharmaceutical industries [4]. Traditional quality management systems often rely on manual documentation, paper-based records, and routine compliance checks, which may increase the risk of human error, incomplete documentation, data manipulation, and operational inefficiencies [5]. With the rapid advancement of digital technologies, pharmaceutical industries are increasingly adopting electronic systems such as Laboratory Information Management Systems (LIMS), Electronic Batch Records (EBR), chromatography data systems, and digital quality management platforms [6]. However, the growing complexity of digital data requires more intelligent systems capable of automated monitoring, predictive analysis, and real-time compliance management [7]. Artificial Intelligence (AI) has emerged as a transformative technology in pharmaceutical quality and regulatory systems [8]. AI refers to advanced computational systems capable of learning from data, identifying patterns, making predictions, and supporting intelligent decision-making [9]. Machine Learning (ML), a major subset of AI, enables systems to continuously improve their analytical performance using historical and real-time datasets [10]. The integration of AI into pharmaceutical quality systems has significantly improved operational efficiency, data accuracy, and regulatory compliance [11]. AI-driven systems are increasingly used to strengthen data integrity by detecting inconsistencies, abnormal trends, unauthorized modifications, and potential compliance risks in analytical and manufacturing records [12]. Advanced machine learning algorithms can automate audit trail review processes, identify suspicious activities, and support risk-based quality monitoring [13]. AI-

assisted electronic documentation systems improve data management through automated report generation, intelligent document review, and electronic signature verification [14]. Furthermore, AI validation has become a critical requirement to ensure the reliability, **reproducibility, and transparency of AI-driven pharmaceutical systems in regulated** environments [15].Digital Quality Assurance (QA) systems integrated with AI technologies support predictive quality monitoring, deviation management, corrective and preventive action (CAPA) systems, and real-time process control [16]. These intelligent systems improve manufacturing efficiency, reduce operational errors, and enhance compliance with regulatory guidelines such as GMP, 21 CFR Part 11, and data integrity requirements [17]. This review discusses the integration of Artificial Intelligence in data integrity, audit trail compliance, electronic documentation, AI validation, and digital quality assurance systems in pharmaceutical industries. The article highlights current applications, regulatory perspectives, advantages, challenges, and future opportunities associated with AI-driven pharmaceutical quality management systems [18].

Data Integrity

Data integrity refers to the accuracy, consistency, completeness, reliability, and security of pharmaceutical data throughout its lifecycle [19]. In pharmaceutical industries, maintaining data integrity is essential during analytical testing, manufacturing operations, quality control, stability studies, and regulatory documentation [20]. Regulatory agencies require pharmaceutical companies to follow ALCOA and ALCOA+ principles to ensure that data are attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available [21]. Before the integration of Artificial Intelligence (AI), pharmaceutical industries mainly relied on manual data review and paper-based or semi-automated systems [22]. Analysts manually reviewed chromatograms, laboratory records, and manufacturing data to identify deviations or inconsistencies. This process was time-consuming and highly dependent on human observation, increasing the possibility of transcription errors, incomplete documentation, delayed deviation detection, and unauthorized data modification [23].

Managing large analytical datasets was also difficult with traditional systems [24].After AI integration, pharmaceutical industries adopted intelligent systems capable of continuously monitoring analytical and manufacturing data in real time [25]. Machine learning algorithms automatically detect abnormal patterns, inconsistencies, missing information, and suspicious activities within digital records [26]. AI systems can compare historical and real-time datasets to identify unusual trends and compliance risks more efficiently than manual systems [27]. AI-driven software integrated with chromatography data systems, Laboratory Information Management Systems (LIMS), and manufacturing execution systems significantly improves data reliability and security [28]. As a result, AI integration enhances data accuracy, reduces human error, improves traceability, accelerates deviation detection, strengthens cybersecurity, and improves overall regulatory compliance [29]. These advancements support better inspection readiness and reduce the operational workload associated with manual data verification processes [30].

Audit Trail Compliance

Audit trails are electronic records that track all activities related to data generation, modification, deletion, and review within pharmaceutical systems [1]. Regulatory agencies require complete audit trail documentation to ensure transparency, accountability, and traceability of pharmaceutical operations [2]. Before the implementation of AI, audit trail review processes were mainly performed manually by quality assurance personnel [3]. Large volumes of electronic records generated from chromatography systems, manufacturing software, and digital documentation platforms had to be individually reviewed to identify suspicious activities or unauthorized changes [4]. This manual approach was labour-intensive, time-consuming, and associated with the risk of overlooking critical compliance issues [5]. In many pharmaceutical industries, only limited or random audit trail reviews were conducted due to operational limitations [6].The integration of AI has significantly improved audit trail management and compliance monitoring [7]. AI-powered systems can automatically analyze user activities and classify audit trail events according to their risk level [8]. Machine learning algorithms identify abnormal login activities, repeated data modifications, deleted records, unauthorized access attempts, and suspicious operational patterns in real time [9]. AI systems can prioritize critical events for quality review and generate automated compliance reports for regulatory inspections [10]. Predictive analytics further helps pharmaceutical companies identify high-risk operational areas before major compliance failures occur [11]. As a result, AI-driven audit trail systems reduce manual review workload, improve traceability, strengthen accountability, and enhance inspection readiness [12]. These intelligent systems also improve regulatory compliance by enabling faster identification and resolution of potential data integrity violations [13].

Electronic Documentation

Electronic documentation systems are digital platforms used to manage pharmaceutical records, analytical reports, manufacturing documents, batch records, and quality assurance data [14]. Regulatory agencies strongly encourage pharmaceutical industries to adopt secure electronic systems to improve operational efficiency and ensure regulatory compliance [15]. Before AI integration, electronic documentation systems still depended heavily on manual data entry, report preparation, and document review processes [16]. Analysts and quality assurance personnel manually verified documents for completeness, consistency, and compliance with standard operating procedures [17]. Common challenges included typographical errors, duplicate records, missing information, slow document retrieval, and difficulties in maintaining document version control [18]. Paper-based documentation systems further increased storage requirements and reduced workflow efficiency [19].AI integration has transformed electronic documentation systems by enabling intelligent automation and advanced data management capabilities [20]. AI-assisted systems automate data entry, report generation, document verification, and workflow approvals [21]. Natural Language Processing (NLP) technologies can review pharmaceutical documents, identify inconsistencies, detect missing information, and ensure compliance with standard operating procedures and regulatory requirements [22]. AI

systems also improve document retrieval through intelligent search functions and automated indexing [23]. Electronic signature verification and version control mechanisms further enhance documentation security and traceability [24]. As a result, AI-driven electronic documentation systems reduce documentation errors, improve workflow efficiency, accelerate report generation, minimize paper usage, and strengthen compliance with regulatory guidelines such as 21 CFR Part 11 and GMP requirements [25]. These intelligent systems support efficient, paperless, and highly reliable pharmaceutical operations [26].

AI Validation

AI validation refers to the process of ensuring that AI-driven systems consistently perform according to predefined specifications, operational requirements, and regulatory expectations [27]. Validation is particularly important in pharmaceutical industries because analytical and manufacturing operations directly affect product quality and patient safety [28]. Before the integration of AI, traditional computerized system validation mainly focused on software functionality, data processing accuracy, and operational performance [29]. Conventional systems followed fixed programming rules and predefined workflows, making validation relatively straightforward and predictable [30]. However, these systems had limited predictive capabilities and minimal adaptability to changing analytical conditions [1].With the introduction of AI technologies, validation processes have become more complex because AI systems continuously learn from historical and real-time data [2]. AI validation now involves model training verification, algorithm performance testing, risk assessment, bias detection, cybersecurity evaluation, and continuous system monitoring [3]. Explainable Artificial Intelligence (XAI) has become increasingly important because regulatory agencies require transparency and interpretability in AI-driven decision-making processes [4]. Pharmaceutical companies must demonstrate that AI models produce reliable, reproducible, and scientifically justifiable outcomes under various operational conditions [5]. AI systems also require periodic requalification and continuous monitoring to maintain compliance throughout their lifecycle [6]. The integration of validated AI systems improves analytical reliability, predictive accuracy, automation, and operational efficiency [7]. Furthermore, AI validation strengthens regulatory confidence, supports better risk management, and ensures the safe implementation of intelligent technologies in regulated pharmaceutical environments [8].

Digital Quality Assurance Systems

Digital Quality Assurance (QA) systems are computerized platforms designed to monitor, control, and improve pharmaceutical quality processes [9]. These systems support deviation management, change control, corrective and preventive actions (CAPA), batch review, risk assessment, and regulatory compliance activities [10]. Before AI integration, pharmaceutical quality systems mainly depended on manual quality reviews and reactive problem-solving approaches [11]. Quality assurance teams often investigated deviations and quality failures only after they occurred, resulting in delayed corrective actions and increased operational workload [12]. Manual QA systems also involved time-consuming deviation investigations, extensive documentation, slower decision-making, and limited predictive capabilities [13]. As a result, pharmaceutical industries frequently experienced higher batch failure rates and operational inefficiencies [14].The integration of AI has significantly transformed digital quality assurance systems by enabling predictive quality management and intelligent process monitoring [15]. AI-powered QA systems continuously analyze analytical and manufacturing data using machine learning algorithms to identify quality trends, predict failures, and recommend corrective actions before deviations occur [16]. These systems support automated deviation investigations, intelligent CAPA management, predictive risk assessment, and real-time process monitoring [17].

AI-integrated QA platforms also enhance Process Analytical Technology (PAT), continuous manufacturing, and Real-Time Release Testing (RTRT) through automated quality decision-making and intelligent process control [18]. As a result, AI-driven digital QA systems improve product quality, reduce batch failures, accelerate deviation investigations, enhance manufacturing efficiency, and strengthen regulatory compliance [19]. These intelligent quality systems reduce operational costs, improve patient safety, and support continuous process improvement in modern pharmaceutical industries [20].

Integration of 21 CFR Parts 11 with Artificial Intelligence

21 CFR Part 11 is a regulation established by the US Food and Drug Administration that defines the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records in pharmaceutical and regulated industries [21]. This regulation plays a critical role in ensuring data integrity, security, traceability, and regulatory compliance in pharmaceutical manufacturing, analytical laboratories, and quality assurance systems [22]. Traditional compliance with 21 CFR Part 11 mainly depended on manual verification of electronic records, user access controls, audit trail reviews, and documentation management [23]. Although these systems improved paperless operations, they often required extensive manual monitoring, repetitive compliance checks, and significant human intervention, increasing the possibility of human error and operational inefficiencies [24].The integration of Artificial Intelligence (AI) with 21 CFR Part 11 compliant systems has significantly enhanced electronic record management, audit trail monitoring, data security, and regulatory compliance [25]. AI-driven systems can automatically monitor electronic records, identify unusual activities, detect unauthorized data modifications, and ensure secure user authentication in real time [26]. Machine learning algorithms analyze large volumes of pharmaceutical data and identify abnormal trends, suspicious system access, or deviations that may indicate potential compliance risks [27].

AI-assisted systems also improve electronic signature verification, automated workflow approvals, and intelligent document management [28]. Natural Language Processing (NLP) technologies support automated review of electronic records, standard operating procedures, and quality documents to identify missing information or compliance gaps [29]. AI-integrated systems further strengthen audit trail management by

continuously monitoring user activities and generating automated compliance reports for regulatory inspections [30].

The integration of AI with 21 CFR Part 11 compliant systems offers several advantages to pharmaceutical industries [1]. It reduces manual workload, minimizes documentation errors, improves data integrity, enhances traceability, and accelerates compliance monitoring processes [2]. AI-powered compliance systems also improve inspection readiness, support real-time quality assurance, and reduce the risk of regulatory observations related to electronic records and data integrity violations [3]. Furthermore, AI enables predictive compliance management by identifying potential operational risks before they lead to regulatory failures [4]. Overall, the combination of Artificial Intelligence and 21 CFR Part 11 compliance systems represents a major advancement in digital pharmaceutical quality management, supporting more efficient, secure, and intelligent regulatory operations in modern pharmaceutical industries [5].


INTEGRATION OF 21 CFR PART 11 WITH ARTIFICIAL INTELLIGENCE
AI-Powered Compliance and Data Integrity for Pharmaceutical Systems
ELECTRONIC RECORDS
AI monitors, validates and ensures accuracy, completeness and reliability of electronic records in real time.
AUDIT TRAIL MONITORING
AI analyzes user activities, detects unusual patterns and flags suspicious events for quality review.
USER ACCESS CONTROL
AI enhances user authentication by behavioral analysis and ensures only authorized access to systems and data.
ELECTRONIC SIGNATURES
AI verifies electronic signatures, ensures signer identity, intent and authenticity as per Part 11 requirements.
21 CFR PART 11 COMPLIANCE
AI-ENABLED PHARMACEUTICAL SYSTEMS
AI + 21 CFR PART 11
Smart • Secure • Compliant • Reliable
DATA INTEGRITY
AI detects inconsistencies, unauthorized changes, missing data and ensures ALCOA+ compliance.
DOCUMENT MANAGEMENT
AI with NLP reviews documents, identifies missing information, ensures version control and maintains compliance.
COMPLIANCE REPORTING
AI generates automated compliance reports, highlights risks and supports inspection readiness.
CYBERSECURITY ENHANCEMENT
AI identifies potential threats, prevents unauthorized access and protects sensitive pharmaceutical data.
KEY BENEFITS
Improved Data Integrity
Enhanced Regulatory Compliance
Reduced Risk of Data Manipulation
Real-time Monitoring and Alerts
Operational Efficiency and Automation
Better Inspection Readiness
Integrating AI with 21 CFR Part 11 enables pharmaceutical industries to achieve higher data integrity, security, traceability and regulatory compliance in a digital and intelligent environment.

Table.3: Integration of 21 CFR Part 11 with artificial intelligence

Conclusion

Artificial Intelligence (AI) has emerged as a transformative technology in pharmaceutical industries by significantly improving data management, regulatory compliance, and digital quality assurance systems. The integration of AI into pharmaceutical operations has enhanced data integrity, audit trail compliance, electronic documentation, AI validation, and quality assurance processes through intelligent automation, predictive analytics, and real-time monitoring capabilities. AI-driven systems reduce human error, improve analytical accuracy, strengthen traceability, and support efficient decision-making in highly regulated pharmaceutical environments. The application of machine learning and advanced computational technologies has enabled pharmaceutical industries to manage large volumes of analytical and manufacturing data more effectively. AI-assisted audit trail review systems, intelligent electronic documentation platforms, and predictive quality assurance tools improve operational efficiency while ensuring compliance with regulatory guidelines such as GMP and 21 CFR Part 11. Furthermore, AI validation and explainable AI approaches strengthen the reliability, transparency, and reproducibility of AI-based pharmaceutical systems. Despite several advantages, challenges such as regulatory acceptance, cybersecurity concerns, validation complexity, data privacy, and implementation costs still require careful consideration. Continuous advancements in AI technologies, cloud computing, big data analytics, and digital pharmaceutical manufacturing are expected to further improve intelligent quality management systems in the future. The development of fully automated and AI-driven pharmaceutical laboratories may revolutionize pharmaceutical manufacturing, analytical testing, and regulatory compliance practices. Overall, the integration of Artificial Intelligence into pharmaceutical quality and compliance systems represents a major advancement toward smart pharmaceutical industries. AI-powered digital systems not only improve product quality and operational efficiency but also enhance patient safety and regulatory confidence, supporting the future development of intelligent and highly reliable pharmaceutical manufacturing environments.

Conflict of Interests

The authors declare no conflict of interest

Ethics Approval

Not applicable

Funding
This study received no specific funding from public, commercial, or not for profit funding agencies.

AI Tool Declaration
The authors declare that no AI and related tools are used to write the scientific content of this manuscript.

Data Availability
Data will be available on request

References
[1] Patel L, Shukla T, Huang X, Ussery DW, Wang S. Machine learning and artificial intelligence in pharmaceutical research and development: a review. AAPS J. 2021; 23(6):134.
[2] Ahmed Z, Mohamed K, Zeeshan S, Dong X. Artificial intelligence with multifunctional machine learning platform development for better healthcare and precision medicine. Database (Oxford). 2020; 2020: baaa010.
[3] Lo AW. Artificial intelligence in pharmaceutical sciences: opportunities and challenges. Trends Pharmacol Sci. 2022; 43(3):151-63.
[4] Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics. Chemom Intell Lab Syst. 2001;58(2):109-30.
[5] Brereton RG. Chemometrics for pattern recognition. Chichester: Wiley; 2009.
[6] Goodfellow I, Bengio Y, Courville A. Deep learning. Cambridge: MIT Press; 2016.
[7] Erickson BJ, Korfiatis P, Akkus Z, Kline TL. Machine learning for medical imaging. Radiographics. 2017; 37(2): 505-15.
[8] LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015; 521(7553):436-44.
[9] Sharma N, Om H. Usage of machine learning and artificial intelligence in pharmaceutical research. J Drug Deliv Ther. 2021;11(4):150-8.
[10] US Food and Drug Administration. Data integrity and compliance with drug CGMP guidance for industry. Silver Spring (MD): FDA; 2018.
[11] International Council for Harmonisation. ICH guideline Q9 on quality risk management. Geneva: ICH; 2020.
[12] US Food and Drug Administration. CFR - Code of Federal Regulations Title 21 Part 11: Electronic records; electronic signatures. Silver Spring (MD): FDA; 2023.
[13] Waters Corporation. Empower chromatography data software: user guide. Milford (MA): Waters Corporation; 2022.
[14] Thermo Fisher Scientific. Chromeleon chromatography data system: technical overview. Waltham (MA): Thermo Fisher Scientific; 2022.
[15] Pasquini C. Near infrared spectroscopy: fundamentals, practical aspects and analytical applications. J Braz Chem Soc. 2003;14(2):198-219.
[16] Roggo Y, Chalus P, Maurer L, Martinez CL, Edmond A, Jent N. A review of near infrared spectroscopy and chemometrics in pharmaceutical technologies. J Pharm Biomed Anal. 2007;44(3):683-700.
[17] Lavine BK. Chemometrics. Anal Chem. 2000; 72(12): 91R-98R.
[18] Deidda R, Sacré PY, Clavaud M, Coïc L, Avohou H, Hubert P, et al. Vibrational spectroscopy in analysis of pharmaceuticals. TrAC Trends Anal Chem. 2019; 114: 251-67.
[19] Bishop CM. Pattern recognition and machine learning. New York: Springer; 2006.
[20] Baldi P. Autoencoders, unsupervised learning and deep architectures. Proc ICML Workshop Unsupervised Transfer Learn. 2012;27:37-49.
[21] Haykin S. Neural networks and learning machines. 3rd ed. New York: Pearson Education; 2009.
[22] Kumar V, Gupta NV. AI-assisted pharmaceutical quality control and analytical systems. Asian J Pharm Clin Res. 2023;16(2):12-20.
[23] Rajput DS, Kumar A. Machine learning applications in pharmaceutical industries. Int J Pharm Investig. 2022;12(1):25-33.
[24] Chandrasekaran B, Katthula V, Moustakas E. Applications of artificial intelligence in pharmaceutical development and manufacturing. Pharmaceutics. 2023;15(3):742.
[25] Naik A, Banerjee S. Deep learning in pharmaceutical image analysis and defect detection. Int J Pharm Sci Nanotechnol. 2023;16(1):6200-8.
[26] European Medicines Agency. Guideline on computerized systems and electronic data in clinical trials. Amsterdam: EMA; 2023.
[27] ISPE. GAMP 5: A risk-based approach to compliant GxP computerized systems. 2nd ed. Tampa (FL): International Society for Pharmaceutical Engineering; 2022.
[28] International Council for Harmonisation. ICH Q10 Pharmaceutical Quality System. Geneva: ICH; 2008.
[29] US Food and Drug Administration. Artificial intelligence and machine learning in drug development and manufacturing discussion paper. Silver Spring (MD): FDA; 2023.
[30] World Health Organization. WHO guidance on good data and record management practices. Geneva: WHO; 2016.